摘要
Objective:To study the effect of leflunomide combined with losartan potassium therapy on renal function and glomerular podocyte injury in patients with diabetic nephropathy.Methods:A total of 82 patients with diabetic nephropathy (CKDIIIa, IIIb stage) who were treated in our hospital between June 2013 and May 2016 were selected as the research subjects, random number table was used to divide them into leflunomide (LEF) group and control group who received leflunomide combined with losartan potassium therapy and losartan potassium monotherapy respectively. Before treatment and 8 weeks after treatment, serum contents of renal function indexes, RAAS molecules and inflammatory factors as well as urine contents of podocyte damage proteins were determined.Results:8 weeks after treatment, serum Scr, BUN, CysC, PRA, AT-II, ALD, IL-1β, IL-6 and TNF-α contents, urine ACR levels as well as podocalyxin, nephrin, CA2AP and podocin contents of both groups of patients were significantly lower than those before treatment, and serum Scr, BUN, CysC, IL-1β, IL-6 and TNF-α contents, urine ACR level as well as podocalyxin, nephrin, CA2AP and podocin contents of LEF group were significantly lower than those of control group, serum PRA, AT-II, ALD contents had no significant difference with control group.Conclusion:Leflunomide combined with losartan potassium therapy can improve the renal function of patients with diabetic nephropathy, and inhibit the inflammatory response injury to glomerular podocyte.
